1035 related articles for article (PubMed ID: 32582155)
1. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
3. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
[TBL] [Abstract][Full Text] [Related]
4. Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.
Malherbe DC; Vang L; Mendy J; Barnette PT; Spencer DA; Reed J; Kareko BW; Sather DN; Pandey S; Wibmer CK; Robins H; Fuller DH; Park B; Lakhashe SK; Wilson JM; Axthelm MK; Ruprecht RM; Moore PL; Sacha JB; Hessell AJ; Alexander J; Haigwood NL
Front Immunol; 2020; 11():626464. PubMed ID: 33658998
[TBL] [Abstract][Full Text] [Related]
5. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
[TBL] [Abstract][Full Text] [Related]
6. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
7. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
[TBL] [Abstract][Full Text] [Related]
9. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
10. Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein.
van Haaren MM; McCoy LE; Torres JL; Lee W; Cottrell CA; Copps JL; van der Woude P; Yasmeen A; de Taeye SW; Torrents de la Peña A; Moore JP; Burton DR; Klasse PJ; Ward AB; Sanders RW; van Gils MJ
J Virol; 2021 Aug; 95(17):e0009421. PubMed ID: 34076487
[TBL] [Abstract][Full Text] [Related]
11. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
[TBL] [Abstract][Full Text] [Related]
12. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.
Seaman MS; Leblanc DF; Grandpre LE; Bartman MT; Montefiori DC; Letvin NL; Mascola JR
Virology; 2007 Oct; 367(1):175-86. PubMed ID: 17599382
[TBL] [Abstract][Full Text] [Related]
13. Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicity-Mediating Antibodies in a Rabbit Vaccination Model.
Karlsson I; Borggren M; Jensen SS; Heyndrickx L; Stewart-Jones G; Scarlatti G; Fomsgaard A
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):206-217. PubMed ID: 28982260
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
15. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
Kothe DL; Decker JM; Li Y; Weng Z; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Salazar-Gonzalez JF; Moldoveanu Z; Mestecky J; Gao F; Haynes BF; Shaw GM; Muldoon M; Korber BT; Hahn BH
Virology; 2007 Mar; 360(1):218-34. PubMed ID: 17097711
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
17. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
18. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
